Standardizing of Mesothelioma and Pseudomyxoma Care

Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a major comprehensive treatment of peritoneal surface malignancies. This multimodal approach has proved to be an effective curative treatment or a salvage therapy for a number of patients suffering from peritoneal surface malignancies and is currently the standard of care for appendiceal epithelial neoplasms and Pseudomyxoma peritonei (PMP) syndrome as well as diffuse malignant peritoneal mesothelioma (DMPM). Unfortunately, practices of CRS/HIPEC are widely variable in terms of technical particularities and antimitotic agents, which have produced heterogeneous and no comparable results. Since no single technique has so far demonstrated its superiority over the others, standardization of such practices may enhance patient outcomes, improve care standards and produce homogeneous data that permits systematic comparisons across all centers that offer this procedure.